Co-Authors
This is a "connection" page, showing publications co-authored by Corrado Campochiaro and Giulio Cavalli.
Connection Strength
3.280
-
Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". Circulation. 2018 05 29; 137(22):2421-2422.
Score: 0.770
-
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. J Clin Rheumatol. 2021 Jun 01; 27(4):e143-e146.
Score: 0.237
-
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
Score: 0.232
-
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatology (Oxford). 2021 01 05; 60(1):465-467.
Score: 0.231
-
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020; 11:598308.
Score: 0.230
-
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
Score: 0.221
-
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
Score: 0.220
-
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 25; 21(1):69.
Score: 0.203
-
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018 12 04; 169(11):819-820.
Score: 0.195
-
Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. Minerva Anestesiol. 2021 08; 87(8):891-902.
Score: 0.059
-
The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. J Clin Med. 2021 May 04; 10(9).
Score: 0.059
-
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
Score: 0.059
-
Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvasc Res. 2021 01; 133:104071.
Score: 0.056
-
Mavrilimumab for severe COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Nov; 2(11):e662-e663.
Score: 0.056
-
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
Score: 0.056
-
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
Score: 0.056
-
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
Score: 0.055
-
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020 01 01; 59(1):171-175.
Score: 0.054
-
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018 11; 57:e11-e12.
Score: 0.049
-
Myocarditis: An Interleukin-1-Mediated Disease? Front Immunol. 2018; 9:1335.
Score: 0.048
-
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. Front Immunol. 2018; 9:1233.
Score: 0.048
-
Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017; 6(6):e1318237.
Score: 0.045
-
Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. Oncoimmunology. 2016 Jul; 5(7):e1181244.
Score: 0.042